Peptimmune’s PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and
The concerned EU member states concluded that the profile of Toctino (alitretinoin) is favorable for use in adults who suffer from severe chronic hand eczema that is unresponsive
The primary objective of Mayo’s study is to assess renal, neurohumoral and non-invasive hemodynamic physiologic parameters of intravenous infusions of CD-NP in patients with heart failure. Key assessments
The patent describes a global whole genome amplification methodology using composite DNA/RNA primers able to anneal to multiple sites within the template polynucleotide. The resulting amplified nucleic acid
A Phase I-II safety and efficacy trial is planned for completion by the end of 2008. This study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled, Phase I-II
Under the terms of the agreement, Cytochroma has granted Mitsubishi Tanabe Pharma (MTPC) an exclusive license to develop, manufacture and commercialize CTA018 in the US and Asia. Cytochroma
In collaboration with Merck & Co, deforolimus is currently being evaluated in multiple clinical trials, both alone and in combination with other therapies, for the treatment of patients
Patient recruitment has now commenced for the trial, with the first patients expected to receive their Biopumps within six weeks. The trial is taking place at the Hadassah
The multi-center, Phase I study of oral IPI-493 is designed as a dose-escalation trial in patients with advanced solid tumors. The primary objectives of the study are to
The stem cell line, called BG01 Olig2-GFP, is engineered to track the Olig2 gene, a neural lineage marker. The Olig2 gene controls a protein that maintains a neural
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.